ArticleTherapeutic advances in hematology2011
Salvage therapy for relapsed or refractory acute myeloid leukemia.
Article in Therapeutic advances in hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- Trial
- Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.Cancer · 2018Trial
- Is There (Still) a Place for Sequential Conditioning?Current oncology (Toronto, Ont.) · 2025Review
- Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.Journal of cancer research and clinical oncology · 2022Article
- Cost-effectiveness of gilteritinib for relapsed/refractoryJournal of managed care & specialty pharmacy · 2021Article
- Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML.Frontiers in oncology · 2021Article
- Inhibitory effects of SEL201 in acute myeloid leukemia.Oncotarget · 2019Article
- Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia.Scientific reports · 2019Article
- Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.Blood advances · 2018Article
- Article
- Therapies for acute myeloid leukemia: vosaroxin.OncoTargets and therapy · 2017Review
- Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2015Article
- Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There are a significant number of patients diagnosed with acute leukemia who either fail to achieve remission or who relapse thereafter. Challenges in treating this patient population include accurately assessing prognosis of disease and whether remission can be achieved; assessing the ability of patients to tolerate aggressive salvage therapies; choosing a salvage therapy that is most likely to succeed; and identifying suitable patients for hematopoietic stem cell transplantation. Despite the development of a variety of new investigational therapies, relapsed or refractory acute myeloid Leukemia remains a difficult clinical problem. Clinicians will need to consider all currently available approaches, including cytotoxic chemotherapy, targeted agents, and allogeneic stem cell transplantation, to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.